Third Harmonic Bio

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

THRD

Biotech

News

Health Care

Movers

Trading Ideas

General

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% while reviewing strategic options.

Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape

Price Action

Pre-Market Outlook

Markets

COGT

NPCE

SLRN

TKNO

TSLA

YMAB

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

ACIC

APEI

IMKTA

MNSO

NETD

Ingles Markets, Tesla And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Third Harmonic Bio Inc

Earnings

Press Releases

Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference

Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Third Harmonic Bio to Participate in Upcoming Investor Conferences

Third Harmonic Bio to Participate in Upcoming Investor Conferences in September

Third Harmonic Bio Announces Third Quarter 2024 Financial Results

Third Harmonic Bio to Participate in Upcoming Investor Conferences in November

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Biote

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

MBX Biosciences

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

scPharmaceuticals

Septerna

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Veru

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Third Harmonic Bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga